• Medidata opened its 15th NEXT Shanghai event, framing the agenda around “AI for Impact” in clinical development.
• Management outlined an AI-led platform strategy aimed at helping China biopharma scale global R&D, targeting faster trial execution.
• Executives showcased the AI companion Dot as a workflow tool across study, patient, and data functions to improve trial efficiency.
• Medidata highlighted its clinical dataset spanning 38,000 studies with more than 12 million patients as a basis for AI deployment.
• Product focus included the launch of Medidata Plus, positioned to support end-to-end, AI-enabled trial operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medidata Solutions Inc. published the original content used to generate this news brief on September 03, 2026, and is solely responsible for the information contained therein.